CoreMedic GmbH secured Series B funding led by MIG Capital to advance its innovative transcatheter repair system for mitral valve insufficiency.

Target Company Overview

CoreMedic GmbH is an innovative medical technology company focused on cardiology, located in Radolfzell, Germany. Founded in 2012 as a spin-off from the Heart Center of the University of Bern, Switzerland, CoreMedic's primary mission is to develop its novel treatment concept, ChordArt, for mitral valve insufficiency. The company has successfully demonstrated the surgical application of its ChordArt implant, backed by five-year data confirming its stability, safety, and effectiveness in multiple patients.

With its unique transcatheter technology for mitral valve reconstruction, CoreMedic offers a minimally invasive alternative to conventional surgical methods, significantly reducing the burden on patients and facilitating quicker recovery times. These innovations grant access to treatment for patients deemed unfit for traditional open-heart surgery.

Industry Overview in Germany

The prevalence of mitral valve insufficiency (mitral regurgitation, MR) affects over 24 million patients globally, presenting a considerable unmet medical need. This condition, resulting from structural damage to